Home

dignity not to mention Pitfalls pasi 90 The room graduate Mark down

JCM | Free Full-Text | Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
JCM | Free Full-Text | Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study

Moderate to severe plaque psoriasis | CIMZIA® (certolizumab pegol)
Moderate to severe plaque psoriasis | CIMZIA® (certolizumab pegol)

Tildrakizumab in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analyses on Efficacy, Time to Relapse, Long-Term Safety in Elderly Population and Predictability From The reSURFACE 1 and reSURFACE 2 Phase III Clinical Trials -
Tildrakizumab in Patients with Moderate-to-Severe Psoriasis: Post-Hoc Analyses on Efficacy, Time to Relapse, Long-Term Safety in Elderly Population and Predictability From The reSURFACE 1 and reSURFACE 2 Phase III Clinical Trials -

Figure 2 | Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials | SpringerLink
Figure 2 | Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials | SpringerLink

Plaque Psoriasis Efficacy | Enbrel® (etanercept)
Plaque Psoriasis Efficacy | Enbrel® (etanercept)

PASI 90 / 100 , DLQI 0 / 1 , and IL-17 Receptor / Cytokine : Does it Make a Difference and Are We Ambitious Enough ? | Semantic Scholar
PASI 90 / 100 , DLQI 0 / 1 , and IL-17 Receptor / Cytokine : Does it Make a Difference and Are We Ambitious Enough ? | Semantic Scholar

Skin Clearance | Efficacy | RINVOQ® (upadacitinib)
Skin Clearance | Efficacy | RINVOQ® (upadacitinib)

SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)

STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis
STELARA® (ustekinumab) Efficacy Data: Moderate to Severe Plaque Psoriasis

PASI-75 and PASI-90 responder rates at weeks 4, 12, 24, and 52.... | Download Scientific Diagram
PASI-75 and PASI-90 responder rates at weeks 4, 12, 24, and 52.... | Download Scientific Diagram

Evolution of psoriasis endpoint use - IQVIA
Evolution of psoriasis endpoint use - IQVIA

Emerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis - European Medical Journal
Emerging Insights in the Treatment of Psoriasis and Psoriatic Arthritis - European Medical Journal

A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis - ScienceDirect
A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis - ScienceDirect

Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare) | HTML | Acta Dermato-Venereologica
Patients' and Physicians' Preferences for Systemic Psoriasis Treatments: A Nationwide Comparative Discrete Choice Experiment (PsoCompare) | HTML | Acta Dermato-Venereologica

What Does Efficacy Cost? Evidence for Relative Cost-Effectiveness of Biologic Therapies for Psoriasis - Practical Dermatology
What Does Efficacy Cost? Evidence for Relative Cost-Effectiveness of Biologic Therapies for Psoriasis - Practical Dermatology

Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study* - Reich - 2021 - British Journal of Dermatology - Wiley Online Library
Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study* - Reich - 2021 - British Journal of Dermatology - Wiley Online Library

Novartis' plaque psoriasis drug keeps skin clear 4 years post treatment
Novartis' plaque psoriasis drug keeps skin clear 4 years post treatment

Pediatric PsO Treatment Information | COSENTYX® (secukinumab) | HCP
Pediatric PsO Treatment Information | COSENTYX® (secukinumab) | HCP

SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)
SKYRIZI® Efficacy In Moderate to Severe Plaque Psoriasis (Ps)

SIMPONI ARIA® Psoriatic Arthritis Efficacy: PASI Response | HCP
SIMPONI ARIA® Psoriatic Arthritis Efficacy: PASI Response | HCP

Figure 1 | Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses | SpringerLink
Figure 1 | Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses | SpringerLink

PASI 75, PASI 90, and PASI 100 response at week 12 for patients... | Download Scientific Diagram
PASI 75, PASI 90, and PASI 100 response at week 12 for patients... | Download Scientific Diagram

Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis | Chinese Medical Journal
Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis | Chinese Medical Journal

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomize
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomize